Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy - PubMed (original) (raw)

Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy

Farnaz Taghizadeh et al. Mol Cancer Ther. 2007 Jan.

Abstract

Patients with advanced colorectal cancer continue to have poor outcomes because of therapy-refractory disease. We previously showed that secreted protein acidic and rich in cysteine (SPARC) gene and protein could function as a chemotherapy sensitizer by enhancing tumor regression in response to radiation and chemotherapy in tumor xenograft models of chemotherapy-resistant tumors. This function of SPARC was gleamed from a microarray analysis that also revealed down-regulation of the vitamin D receptor (VDR) in therapy-refractory colorectal cancer cells. This study examines the potential synergistic effect of SPARC and vitamin D, which up-regulates VDR, in enhancing chemotherapy response in colorectal cancer. Using MIP101 colorectal cancer cell lines and SPARC-overexpressing MIP101 cells, we were able to show that, in the presence of SPARC, exposure to low doses of 1alpha,25-dihydroxyvitamin D(3) significantly reduces cell viability, enhances chemotherapy-induced apoptosis, and inhibits the growth of colorectal cancer cells. Moreover, in tumor xenograft mouse models, up-regulation of VDR was seen in tumors that had the greatest regression following treatment that combined SPARC with chemotherapy. Therefore, our findings reveal a synergistic effect between SPARC and low doses of 1alpha,25-dihydroxyvitamin D(3) that further augments the sensitivity of tumors to chemotherapy. This combination may prove to be a useful adjunct in the treatment of colorectal cancer, especially in those patients with therapy-refractory disease.

PubMed Disclaimer

Cited by

Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1.
Xu YZ, Heravi M, Thuraisingam T, Di Marco S, Muanza T, Radzioch D. Xu YZ, et al. Mol Cancer. 2010 Aug 5;9:210. doi: 10.1186/1476-4598-9-210. Mol Cancer. 2010. PMID: 20687958 Free PMC article.
Vitamin D and cancer: a review of molecular mechanisms.
Fleet JC, DeSmet M, Johnson R, Li Y. Fleet JC, et al. Biochem J. 2012 Jan 1;441(1):61-76. doi: 10.1042/BJ20110744. Biochem J. 2012. PMID: 22168439 Free PMC article. Review.
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim YB, Tai IT. Rahman M, et al. Neoplasia. 2012 Jul;14(7):624-33. doi: 10.1593/neo.12486. Neoplasia. 2012. PMID: 22904679 Free PMC article.
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA. Schultz CR, et al. Mol Cancer. 2012 Apr 5;11:20. doi: 10.1186/1476-4598-11-20. Mol Cancer. 2012. PMID: 22480225 Free PMC article.
A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo.
Rahman M, Chan AP, Tang M, Tai IT. Rahman M, et al. PLoS One. 2011;6(11):e26390. doi: 10.1371/journal.pone.0026390. Epub 2011 Nov 1. PLoS One. 2011. PMID: 22069448 Free PMC article.

Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy - PubMed (original) (raw)